Critically, immunotherapeutic treatment with IFNγ must be carefully designed to maximise efficacy and to prevent iatrogenic harm through tumour induction, especially as all upcoming and ongoing clinical trials continue to utilise IFNγ as a potential treatment agent for cancer (Table 1). This evidence concerns the gene IFNG and cancer.